Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomas

Robin Jones • 28 Apr 2020
Sarcoma Doxorubicin Olaratumab

Robin Jones, MBBS, MRCP, MD (Res), Royal Marsden NHS Foundation Trust, London, UK, updates us on recent results published from the ANNOUNCE Phase III study which evaluated the addition of olaratumab to doxorubicin in patients with advanced/metastatic soft tissue sarcoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Robin Jones

0:58
Challenges in advanced GIST: tackling resistance to therapies
Robin Jones • 4 Jun 2023
0:36
Current treatment landscape for patients with advanced gastrointestinal stromal tumor (GIST)
Robin Jones • 3 Jun 2023
1:13
Updated overall survival findings from the Phase III INTRIGUE trial
Robin Jones • 4 Jun 2023
0:34
INTRIGUE: ripretinib versus sunitinib in GIST
Robin Jones • 4 Jun 2023

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals